HomeNeurologicalStroke Recovery: Why the "Six-Month Plateau" Isn't What You Think

Stroke Recovery: Why the "Six-Month Plateau" Isn't What You Think

The six-month mark gets treated as the point where stroke recovery stops. The evidence points to something different — the brain doesn't stop changing, therapy dose usually just drops.

1 Jul 2026·2 min read·RehabGoWhere Editorial

The six-month mark after a stroke gets treated as a kind of deadline — the point where recovery is said to plateau, and further gains become unlikely. It's one of the most repeated numbers in stroke recovery, and it's misleading in a way that has real consequences for how much therapy people pursue after that point.

Where the Six-Month Number Comes From

Older studies observed that the rate of improvement slows considerably after around six months, and that observation calcified into "recovery stops here." Peer-reviewed work directly investigating this — including a study specifically examining the critical window for neuroplasticity — found evidence of a long-lasting period of enhanced plasticity extending beyond one year post-stroke, enabling continued improvement at late chronic stages.

Line graph contrasting the assumed "plateau" (flat line after 6 months) with documented continued recovery gains extending past a year.

What's Actually Changing After Six Months

The brain doesn't stop being able to change. What changes is the threshold for triggering that change. In the acute phase, new connections form readily in response to practice. In the chronic phase, the brain can still form new connections — it just takes more consistent, higher-volume input to drive it.

It isn't that the brain can't change after six months. It's that the dose of practice most people receive isn't enough to change it.

The Real Bottleneck: Dose

Standard outpatient therapy sessions often include only 30 to 50 repetitions of an affected-limb movement. Motor learning research suggests hundreds to thousands of repetitions are typically needed to drive meaningful neural change. That gap — not a biological cutoff — is the more likely explanation for why recovery appears to plateau around the point where therapy intensity usually drops off.

Bar chart comparing typically delivered therapy repetitions (30-50 per session) against the hundreds-to-thousands suggested to drive meaningful neural change.

What This Means in Practice

None of this means recovery is guaranteed or unlimited at any stage — lesion size and location, and general health, all still matter. It means the six-month mark isn't a hard biological stopping point, and continued, sufficiently intensive practice remains a reasonable basis for pursuing further gains well beyond it.

Don't treat "no more progress expected after six months" as settled fact — ask what evidence that assessment is based on
Ask specifically about repetition volume in therapy sessions, not just session frequency
Consider whether current therapy intensity matches what's needed to drive further change, not just what's routinely offered
Approaches like constraint-induced movement therapy are built around exactly this — high-repetition, forced use of the affected side
A plateau in one therapy setting doesn't necessarily mean a biological plateau

Key Takeaways

The "six-month plateau" reflects typical therapy dose and access patterns more than a hard biological limit.
Peer-reviewed research has found evidence of enhanced neuroplasticity extending beyond a year post-stroke in some patients.
Standard outpatient sessions often deliver far fewer repetitions than motor learning research suggests are needed for change.
The threshold for triggering neuroplastic change rises over time — it doesn't disappear.
Continued, sufficiently intensive practice remains a reasonable basis for pursuing gains well beyond six months.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a registered physiotherapist or healthcare professional for advice specific to your condition.

Category

Neurological

Stroke recovery, neuroplasticity, Parkinson's disease, and brain-body rehabilitation.